Disclosure of individual pharmacogenomic results in research projects: when and what kind of information to return to research participants

Author： Korol Sandra   Hurlimann Thierry   Godard Béatrice   de Denus Simon  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.6, 2013-04, pp. : 675-688

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Return of research results from pharmacogenomic versus disease susceptibility studies: what’s drugs got to do with it?

By Dressler Lynn G  

Pharmacogenomics, Vol. 13, Iss. 8, 2012-06 ,pp. : 935-949

Future Medicine

Access to resources Recommend Favorite

Return of Genetic Research Results to Participants and Families: IRB Perspectives and Roles

By  

THE JOURNAL OF LAW, MEDICINE & ETHICS, Vol. 43, Iss. 3, 2015-09 ,pp. : 502-513

John Wiley & Sons Inc

Access to resources Recommend Favorite

INTRODUCTION: Return of Research Results: What About the Family?

By  

THE JOURNAL OF LAW, MEDICINE & ETHICS, Vol. 43, Iss. 3, 2015-09 ,pp. : 437-439

John Wiley & Sons Inc

Access to resources Recommend Favorite

Preferences Regarding Return of Genomic Results to Relatives of Research Participants, Including after Participant Death: Empirical Results from a Cancer Biobank

By  

THE JOURNAL OF LAW, MEDICINE & ETHICS, Vol. 43, Iss. 3, 2015-09 ,pp. : 464-475

John Wiley & Sons Inc

Access to resources Recommend Favorite

Considerations for Returning Research Results to Culturally Diverse Participants and Families of Decedents

By  

THE JOURNAL OF LAW, MEDICINE & ETHICS, Vol. 43, Iss. 3, 2015-09 ,pp. : 569-575

John Wiley & Sons Inc

Access to resources Recommend Favorite